Nothing Special   »   [go: up one dir, main page]

HUP0004821A2 - Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása - Google Patents

Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása

Info

Publication number
HUP0004821A2
HUP0004821A2 HU0004821A HUP0004821A HUP0004821A2 HU P0004821 A2 HUP0004821 A2 HU P0004821A2 HU 0004821 A HU0004821 A HU 0004821A HU P0004821 A HUP0004821 A HU P0004821A HU P0004821 A2 HUP0004821 A2 HU P0004821A2
Authority
HU
Hungary
Prior art keywords
soft
solution
micronizing
active ingredient
dry mixture
Prior art date
Application number
HU0004821A
Other languages
English (en)
Inventor
Hideki Ito
Yasuko Soeda
Hiromitsu Yoshida
Original Assignee
Fujisawa Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.
Publication of HUP0004821A2 publication Critical patent/HUP0004821A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A találmány egy lágy pelletté formázott gyógyszerkészítményt nyújt,mely a gyógyszerészeti előállítási eljárásoknál könnyen kezelhető,irritációs reakciókat az alkalmazójánál nem vált ki és a belélegezendőhatóanyag részecske méretbeli eloszlása szabályozható. A 100 m, és 1mm átlagos átmérőjű részecskékből álló lágy pellet gyógyszerkészítménya tárgyalt technológiával előállítható, például oly módon, hogy azönmagában agglomeratív tulajdonságokkal rendelkező hatóanyag cukoroldatban - például laktóz oldatban - elkészített oldatát vagyszuszpenzióját száraz keverékké szárítják, a száraz keveréketmikronizálják és a nyert, finoman mikronizált port egy forgódobbangörgetik. Ó
HU0004821A 1997-12-03 1998-11-16 Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása HUP0004821A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP33322897 1997-12-03
PCT/JP1998/005159 WO1999027911A1 (fr) 1997-12-03 1998-11-16 Medicament en pastilles souples et procede de fabrication

Publications (1)

Publication Number Publication Date
HUP0004821A2 true HUP0004821A2 (hu) 2001-06-28

Family

ID=18263764

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004821A HUP0004821A2 (hu) 1997-12-03 1998-11-16 Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása

Country Status (16)

Country Link
EP (1) EP1036562A1 (hu)
KR (1) KR20010032303A (hu)
CN (1) CN1283991A (hu)
AR (1) AR015491A1 (hu)
AU (1) AU1054399A (hu)
BR (1) BR9815345A (hu)
CA (1) CA2310826A1 (hu)
HU (1) HUP0004821A2 (hu)
ID (1) ID28057A (hu)
IL (1) IL136251A0 (hu)
NO (1) NO20002831L (hu)
NZ (1) NZ504711A (hu)
PL (1) PL340736A1 (hu)
TR (1) TR200001596T2 (hu)
WO (1) WO1999027911A1 (hu)
ZA (1) ZA9810882B (hu)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6750324B1 (en) 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20030147882A1 (en) 1998-05-21 2003-08-07 Alan Solomon Methods for amyloid removal using anti-amyloid antibodies
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
ITMI20012174A1 (it) * 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1417958A1 (en) * 2002-11-08 2004-05-12 Pari GmbH Wet granulation process
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
WO2005004875A1 (ja) * 2003-07-14 2005-01-20 Sankyo Company, Limited 経肺投与用医薬組成物
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2182983B1 (en) 2007-07-27 2014-05-21 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases with humanised anti-abeta antibodies
BRPI0814876A2 (pt) 2007-07-31 2014-09-30 Limerick Biopharma Inc Análogos de pirona fosforilados e métodos
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
MY168300A (en) 2011-09-14 2018-10-25 Shionogi & Co Pharmaceutical Composition for Inhalation
TWI745396B (zh) 2016-07-12 2021-11-11 日商鹽野義製藥股份有限公司 吸入用醫藥組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9001635D0 (en) * 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
CA2131285C (en) * 1992-03-10 2004-06-29 Lewis James Baskeyfield Pharmaceutical inhalation compositions
AU4066693A (en) * 1992-12-23 1994-07-19 Bernhard Hugemann Compacted drug body for use in the mechanical generation of inhalable active-substance particles
JPH08291072A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 吸入用粉末製剤用結晶とその製造方法
JPH08291073A (ja) * 1995-04-22 1996-11-05 Kissei Pharmaceut Co Ltd 医薬品組成物及びその製造方法

Also Published As

Publication number Publication date
WO1999027911A1 (fr) 1999-06-10
PL340736A1 (en) 2001-02-26
TR200001596T2 (tr) 2000-12-21
NO20002831D0 (no) 2000-06-02
AU1054399A (en) 1999-06-16
CA2310826A1 (en) 1999-06-10
EP1036562A1 (en) 2000-09-20
KR20010032303A (ko) 2001-04-16
CN1283991A (zh) 2001-02-14
ID28057A (id) 2001-05-03
AR015491A1 (es) 2001-05-02
NO20002831L (no) 2000-08-03
NZ504711A (en) 2002-02-01
BR9815345A (pt) 2000-11-21
ZA9810882B (en) 1999-05-26
IL136251A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
HUP0004821A2 (hu) Lágy pellet alakjában lévő gyógyszerkészítmény és előállítása
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
EP0322137B1 (en) Spray dried ibuprofen
NZ535284A (en) Microparticles of glycopyrrolate for the treatment of respiratory diseases
CA2347856A1 (en) Dry powder for inhalation
SE0002822D0 (sv) Electro-powder
KR840000226A (ko) 신규한 형태의 의약품의 제조방법
MY115688A (en) Pharmaceutical composition for administration by inhalation
EE03222B1 (et) Inhaleeritavad ravimpreparaadid, protsess nende valmistamiseks ja seade nende kasutamiseks
PL334493A1 (en) Novel inhalable preparation of 0.28 to 0.38 g/ml bulk density containing budesonide
HUP0104478A2 (hu) Őrlési eljárás finoman őrölt gyógyszerek előállítására
HUP0000843A2 (hu) Formoterolt tartalmazó, 028-0,38 g/ml szórósűrűségű, új inhalációs gyógyszerforma
JPH06192113A (ja) 生薬類の造粒方法および固形製剤
HUP0300334A2 (hu) Gyógyászati készítmények és eljárások azok elżállítására
AU1434700A (en) Dry powder pharmaceutical formulation
NZ236631A (en) Process for the preparation of a spray dried powdered pharmaceutical formulation of naproxen
HUP0000755A2 (hu) Terbutalin-szulfátot tartalmazó, 0,28-0,38 g/ml szórósűrűségű, új inhalációs gyógyszerforma, eljárás előállítására és alkalmazása
HK1048064A1 (en) Suspension of an epi-hne protein, process of preparation thereof, dry powder aerosol derived therefrom, pharmaceutical compositions containing said suspension or aerosol, and their uses
SE0003082D0 (sv) Metered electro-dose
Podczeck et al. Influence of the standing time of the extrudate and speed of rotation of the spheroniser plate on the properties of pellets produced by extrusion and spheronization
HUP0000494A2 (hu) Izzadásgátló kozmetikai készítmény
TH43266A (th) สูตรผสมใหม่สำหรับการสูดลมหายใจเข้า
TH53621B (th) สูตรผสมใหม่สำหรับการสูดลมหายใจเข้า